-
Something wrong with this record ?
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
KJ. Savage, SM. Horwitz, R. Advani, JH. Christensen, E. Domingo-Domenech, G. Rossi, F. Morschhauser, O. Alpdogan, C. Suh, K. Tobinai, A. Shustov, M. Trneny, S. Yuen, PL. Zinzani, L. Trümper, T. Ilidge, OA. O'Connor, B. Pro, H. Miao, V. Bunn, K....
Language English Country United States
Document type Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Grant support
P30 CA008748
NCI NIH HHS - United States
NLK
Directory of Open Access Journals
from 2016
PubMed Central
from 2016
Europe PubMed Central
from 2016
ROAD: Directory of Open Access Scholarly Resources
from 2016
- MeSH
- Lymphoma, Large-Cell, Anaplastic * chemically induced therapy MeSH
- Ki-1 Antigen MeSH
- Brentuximab Vedotin MeSH
- Cyclophosphamide adverse effects MeSH
- Doxorubicin adverse effects MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Prednisone adverse effects MeSH
- Hematopoietic Stem Cell Transplantation * MeSH
- Vincristine adverse effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Research Support, N.I.H., Extramural MeSH
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility. The double-blind randomized phase 3 ECHELON-2 study (#NCT01777152; clinicaltrials.gov) demonstrated improved progression-free survival (PFS) and overall survival with frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP). Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. Median PFS follow-up was 47.57 months. The PFS hazard ratio was 0.36, equating to a 64% reduction in the risk of a PFS event in patients who underwent SCT. The median PFS in patients who underwent SCT was not reached, vs 55.66 months in patients who did not undergo SCT. PFS results favored the use of SCT in both ALK- ALCL and non-ALCL subgroups. These data support the consideration of consolidative SCT in patients with CD30+PTCL who achieve CR following treatment with A+CHP.
Azienda Ospedaliera Spedali Civili di Brescia Brescia Italy
Blood and Marrow Transplant Program Stanford Cancer Center Stanford CA
Calvary Mater Newcastle Hospital Waratah NSW Australia
Department of Haematology Odense University Hospital Odense Denmark
Department of Hematology and Medical Oncology Universitätsmedizin Göttingen Göttingen Germany
Hematology Division National Cancer Center Hospital Tokyo Japan
Institut Catala D'oncologia L'Hospitalet de Llobregat Barcelona Spain
MD Anderson Cancer Center University of Texas Houston TX
Memorial Sloan Kettering Cancer Center New York NY
Millennium Pharmaceuticals Inc Cambridge MA
NewYork Presbyterian Columbia University Irving Medical Center New York NY
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22033092
- 003
- CZ-PrNML
- 005
- 20240313104620.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1182/bloodadvances.2020003971 $2 doi
- 035 __
- $a (PubMed)35470385
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Savage, Kerry J $u Centre for Lymphoid Cancer and Division of Medical Oncology, British Columbia Cancer, Vancouver, BC, Canada $1 https://orcid.org/0000000258359863
- 245 10
- $a Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2 / $c KJ. Savage, SM. Horwitz, R. Advani, JH. Christensen, E. Domingo-Domenech, G. Rossi, F. Morschhauser, O. Alpdogan, C. Suh, K. Tobinai, A. Shustov, M. Trneny, S. Yuen, PL. Zinzani, L. Trümper, T. Ilidge, OA. O'Connor, B. Pro, H. Miao, V. Bunn, K. Fenton, M. Fanale, M. Puhlmann, S. Iyer
- 520 9_
- $a Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility. The double-blind randomized phase 3 ECHELON-2 study (#NCT01777152; clinicaltrials.gov) demonstrated improved progression-free survival (PFS) and overall survival with frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP). Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. Median PFS follow-up was 47.57 months. The PFS hazard ratio was 0.36, equating to a 64% reduction in the risk of a PFS event in patients who underwent SCT. The median PFS in patients who underwent SCT was not reached, vs 55.66 months in patients who did not undergo SCT. PFS results favored the use of SCT in both ALK- ALCL and non-ALCL subgroups. These data support the consideration of consolidative SCT in patients with CD30+PTCL who achieve CR following treatment with A+CHP.
- 650 _2
- $a brentuximab vedotin $7 D000079963
- 650 _2
- $a cyklofosfamid $x škodlivé účinky $7 D003520
- 650 _2
- $a doxorubicin $x škodlivé účinky $7 D004317
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a antigen Ki-1 $7 D017730
- 650 12
- $a anaplastický velkobuněčný lymfom $x chemicky indukované $x terapie $7 D017728
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a prednison $x škodlivé účinky $7 D011241
- 650 _2
- $a vinkristin $x škodlivé účinky $7 D014750
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Horwitz, Steven M $u Memorial Sloan-Kettering Cancer Center, New York, NY
- 700 1_
- $a Advani, Ranjana $u Blood and Marrow Transplant Program, Stanford Cancer Center, Stanford, CA
- 700 1_
- $a Christensen, Jacob Haaber $u Department of Haematology, Odense University Hospital, Odense, Denmark
- 700 1_
- $a Domingo-Domenech, Eva $u Institut Catala D'oncologia, L'Hospitalet de Llobregat, Barcelona, Spain $1 https://orcid.org/000000018907090X
- 700 1_
- $a Rossi, Giuseppe $u Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
- 700 1_
- $a Morschhauser, Franck $u Department of Hematology, Université de Lille, Centre Hospitalier Universitaire Lille, ULR 7365, Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), Lille, France $1 https://orcid.org/0000000237149824
- 700 1_
- $a Alpdogan, Onder $u Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA $1 https://orcid.org/0000000248325344
- 700 1_
- $a Suh, Cheolwon $u Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- 700 1_
- $a Tobinai, Kensei $u Hematology Division, National Cancer Center Hospital, Tokyo, Japan
- 700 1_
- $a Shustov, Andrei $u University of Washington Medical Center, Seattle, WA
- 700 1_
- $a Trneny, Marek $u First Department of Medicine-Hematology, Charles University General Hospital and First Faculty of Medicine, Nové Město, Czech Republic $1 https://orcid.org/0000000269526073
- 700 1_
- $a Yuen, Sam $u Calvary Mater Newcastle Hospital, Waratah, NSW, Australia
- 700 1_
- $a Zinzani, Pier Luigi, $d 1959- $u Scientific Institute for Research, Hospitalization and Healthcare Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi, Bologna, Italy $1 https://orcid.org/0000000221122651 $7 xx0314852
- 700 1_
- $a Trümper, Lorenz $u Department of Hematology and Medical Oncology, Universitätsmedizin Göttingen, Göttingen, Germany $1 https://orcid.org/0000000297984573
- 700 1_
- $a Ilidge, Tim $u Division of Cancer Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom $u National Institutes of Health and Research Biomedical Research Center, Manchester Academic Health Sciences, Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom
- 700 1_
- $a O'Connor, Owen A $u E. Couric Cancer Center, University of Virginia, Charlottesville, Virginia, and TG Therapeutics, New York, NY
- 700 1_
- $a Pro, Barbara $u NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY
- 700 1_
- $a Miao, Harry $u Kite Pharma, Santa Monica, CA
- 700 1_
- $a Bunn, Veronica $u Millennium Pharmaceuticals Inc., Cambridge, MA
- 700 1_
- $a Fenton, Keenan $u Seagen Inc., Bothell, WA
- 700 1_
- $a Fanale, Michelle $u Seagen Inc., Bothell, WA
- 700 1_
- $a Puhlmann, Markus $u Seagen Inc., Bothell, WA $1 https://orcid.org/0000000213609910
- 700 1_
- $a Iyer, Swaminathan $u MD Anderson Cancer Center/University of Texas, Houston, TX
- 773 0_
- $w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 6, č. 19 (2022), s. 5550-5555
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35470385 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20240313104616 $b ABA008
- 999 __
- $a ok $b bmc $g 1891699 $s 1184427
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 6 $c 19 $d 5550-5555 $e 2022Oct11 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
- GRA __
- $a P30 CA008748 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20230120
